BBC- Covid: New Oxford vaccine 'ready by the autumn' to tackle mutations
With the emergence of various mutations of SARS-CoV-2 there is still reassuring evidence that existing vaccines are providing good protection, although at a slightly less rate than with the initial variants. Additionally, interim results released by the Oxford/AstraZeneca team showed that vaccination with the Oxford/AstraZeneca COVID-19 vaccine could cut transmission of the virus by up to 67%.
In the following article published in the BBC, Professor Andy Pollard from Oxford University suggests that updating vaccines to make them more effective against mutations is a quick process. With manufacturing processes already established, newer vaccines could be available relatively quickly.
Để đọc thêm theo liên kết dưới đây:
BBC- Covid: New Oxford vaccine 'ready by the autumn' to tackle mutations
New immunisation reference page: Drive-through immunisation clinics
Drive-through immunisation clinics are an alternative venue for supporting vaccine delivery and can assist members of the community to continue to receive recommended immunisations whilst maintaining physical distancing.
Our new reference page highlights the equipment, staffing and logistics to consider when setting up a drive-through clinic.
To access this resource please visit our Tài liệu tham khảo tiêm chủng or follow the link below:
MVEC: Drive-through immunisation clinics
Latest monitoring data confirms safety of COVID-19 vaccines
Data from the UK's independent medicines regulator (MHRA) has confirmed that the safety profile of the approved COVID-19 vaccines (Oxford Astra/Zeneca and Pfizer/BioNTech) remains as high as reported in the clinical trial data that supported those approvals.
With over 10 million doses already delivered, there have been 22,820 reports of suspected side effects with the majority being short-lasting, mild and expected side effects including sore arms and 'flu-like' symptoms.
Để đọc thông cáo báo chí đầy đủ theo liên kết dưới đây:
Latest monitoring data confirms safety of COVID-19 vaccines
CVU Miniseries event February 8, 2021- registration closing soon
COVID-19 vaccines: A Victorian landscape is the first event in our CVU Miniseries for 2021.
Please join us online on Monday the 8th of February at 7pm to hear about COVID-19 vaccine safety and Victorian COVID-19 vaccine rollout information.
To view the full program and to register, please visit our Sự kiện trang.
Registrations for this FREE event will close on Monday the 8th of February at 2pm.
một đoạn ghi âm của COVID-19 vaccines: A Victorian landscape will be accessible on our Cổng thông tin giáo dục sau sự kiện này.
JAMA Pediatrics: Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratio
A recent cohort study conducted at Pennsylvania Hospital, Philadelphia involving 1714 participants assessed maternal and cord blood for the transfer of SARS-CoV-2 antibodies. Trial participants were from various ethnic backgrounds with ages ranging from 28-35 years. IgG and/or IgM was detected in 83 woman at the time of delivery and IgG was detected in the cord blood of 72 of the 83 infants. The transfer of antibodies occurred after symptomatic and asymptomatic infections during pregnancy.
Để đọc bài báo đầy đủ tham khảo liên kết dưới đây:
MVEC eLearning: Use of Multi-Dose Vials
MVEC are excited to launch the next of our eLearning packages. Our eLearning packages are designed to allow immunisation providers consolidate and evaluate their technical skills. Targeted resources are available to assist with our eLearning and a certificate of completion will be made available upon completion of the corresponding eLearning quiz.
Use of Multi-Dose Vials has been designed to demonstrate the safe preparation and storage of vaccines from multi-dose vials that require reconstitution and from those that do not.
You can access Use of Multi-Dose Vials via our Cổng thông tin giáo dục.
Community pharmacies to participate in COVID-19 vaccination program
The Australian Government has announced an expression of interest (EOI) process has begun for community pharmacies to participate in the COVID-19 vaccination program.
Participation is voluntary, with pharmacies needing to demonstrate their capacity, capability and ability to meet high safety standards.
Eligible pharmacies would be able to deliver COVID-19 vaccines to priority populations from phase 2a of the of Australian COVID-19 vaccination rollout strategy (expected to be in May 2021). They would be incentivised to provide both doses of the AstraZeneca COVID-19 vaccine in an effort to increase uptake of the vaccine.
Read more about this in the Health Minister’s statement via the link below:
Community Pharmacy to join COVID-19 vaccine workforce
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Novavax have released interim results for both its UK phase III clinical trial as well as for the phase 2b studies being conducted in South Africa.
The UK phase III clinical trial involves more than 15,000 participants aged 18-84 years. During a period of high transmission with the UK variant of SARS-CoV-2, the preliminary results show an efficacy rate of 89.3%. After review of the vaccine safety database it has also been reported that any adverse events were balanced between both the vaccine and the placebo groups and any serious or severe side effects occurred at low levels.
In the South African phase 2b clinical trial, an efficacy rate of 60% was seen in the HIV-negative cohort, with an overall 49.4% efficacy rate seen across the total 4,400 trial participants (both HIV-negative and HIV positive individuals). During the time of the trial, the South African variant of SARS-CoV-2 was widely circulating.
The Novavax COVID-19 vaccine candidate is a protein-based vaccine utilising a nanoparticle technology platform.
To read the full press release follow the link below:
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Trang tham khảo tiêm chủng mới: Vắc xin COVID-19: câu hỏi thường gặp
Câu hỏi thường gặp về vắc-xin COVID-19 của MVEC đã được thiết kế để giải quyết các thắc mắc phổ biến liên quan đến vắc-xin COVID-19 và bao gồm thông tin về quy trình phát triển vắc-xin, các nhóm ưu tiên, hiệu quả, bảo quản, sử dụng và an toàn của vắc-xin.
Trang này sẽ được cập nhật thường xuyên khi có thêm thông tin.
MVEC: Vắc xin COVID-19: câu hỏi thường gặp
Trang tham khảo tiêm chủng mới: Bệnh tăng cường liên quan đến vắc-xin (VAED)
Với hàng trăm ứng cử viên vắc-xin COVID-19 đang trong các giai đoạn phát triển và phê duyệt khác nhau, việc hiểu rõ về bất kỳ tác dụng phụ nghiêm trọng tiềm ẩn nào là rất quan trọng để đảm bảo sự chấp nhận và tin cậy của vắc-xin.
Trang tham khảo mới của chúng tôi khám phá bệnh tăng cường liên quan đến vắc-xin (VAED). Nó xảy ra khi một biểu hiện nghiêm trọng hơn của bệnh phát triển ở một cá nhân đã được chủng ngừa trước đó, so với khi nhiễm trùng xảy ra mà không được chủng ngừa trước đó. VAED trước đây có liên quan đến nhiễm sốt xuất huyết; Các ứng cử viên vắc-xin RSV, MERS và SARS-CoV-1; cũng như virus sởi.
Đó chỉ là rủi ro về mặt lý thuyết khi xem xét các ứng cử viên vắc xin COVID-19, tuy nhiên, do đó, khả năng VAED đã được theo dõi chặt chẽ trong tất cả các giai đoạn thử nghiệm lâm sàng đối với các ứng cử viên vắc xin COVID-19.
Để biết thêm thông tin, vui lòng tham khảo trang tham khảo của chúng tôi:
MVEC: Bệnh tăng cường liên quan đến vắc-xin (VAED)